Loading
A phase 2 trial of APG-157 in head and neck squamous cell carcinoma, run by Aveta Biomics, Inc., active and no longer recruiting.
Safety and Efficacy of APG-157 in Head and Neck Cancer is a phase 2 interventional study registered as NCT05312710 by Aveta Biomics, Inc., with 24 participants enrolled, started 2022-04-22 and due to reach its primary completion in 2026-12. Interventions recorded: APG-157.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Aveta Biomics and the tag pipeline.
Shares Oropharyngeal cancer (tonsil and base of tongue), Oral cavity cancer (mouth and tongue), Head and neck squamous cell carcinoma and the tag pipeline.
Shares Oropharyngeal cancer (tonsil and base of tongue), Head and neck squamous cell carcinoma and the tag pipeline.
Shares Oral cavity cancer (mouth and tongue), Head and neck squamous cell carcinoma and the tag pipeline.
Shares Oral cavity cancer (mouth and tongue), Head and neck squamous cell carcinoma and the tag pipeline.
Shares Oral cavity cancer (mouth and tongue), Head and neck squamous cell carcinoma and the tag pipeline.
Shares Oral cavity cancer (mouth and tongue) and the tag pipeline.
Shares Head and neck squamous cell carcinoma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/